预约演示
更新于：2025-02-19
Sildenaifl Citrate
枸橼酸西地那非
更新于：2025-02-19
概要
基本信息
简介伟哥可以放松血管壁中的肌肉，增加流向身体特定部位的血液。伟哥用于治疗男性勃起功能障碍（阳痿）。 西地那非的另一个品牌是 Revatio，用于治疗肺动脉高压和提高男性和女性的运动能力。 此页面包含伟哥的特定信息，而不是 Revatio。 西地那非通过阻断磷酸二酯酶 5 (PDE5) 发挥作用，PDE5 是一种促进 cGMP 分解的酶，可调节阴茎中的血流。 它需要性唤起才能起作用。 它还会导致肺部血管扩张。 辉瑞公司最初是在 1989 年发现这种药物的，当时正在寻找治疗与心脏相关的胸痛的方法。 它于 1998 年在美国和欧盟被批准用于医疗用途。 |
药物类型 小分子化药 |
别名 Pahtension、Revatio OD、sildenafil + [41] |
靶点 |
作用机制 PDE5A抑制剂(磷酸二酯酶-5A抑制剂) |
在研适应症 |
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-03-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (韩国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构/序列
分子式C28H38N6O11S |
InChIKeyDEIYFTQMQPDXOT-UHFFFAOYSA-N |
CAS号171599-83-0 |
关联
665
项与 枸橼酸西地那非 相关的临床试验NCT06810284
Effect of Sildenafil in Association to Hypothermia on Survival Without Brain Lesions in Term Neonates with Hypoxic-ischemic Encephalopathy (SHINE): Pharmacokinetic Study - Step 1
NCT06377098
Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-Resource Settings: A Randomized Pilot Feasibility Trial: Pilot Randomized Intrapartum Sildenafil in Mothers
NCT06522854
Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings: A Randomized Pilot Feasibility Trial
100 项与 枸橼酸西地那非 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸西地那非 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸西地那非 相关的专利（医药）
登录后查看更多信息
10,578
项与 枸橼酸西地那非 相关的文献（医药）2025-04-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Identification of Phosphodiesterase type 5 inhibitors (PDE5is) analogues using surface-enhanced Raman scattering and machine learning algorithm
Article
作者: Huang, Jiadong ; He, Hongyuan ; Li, Yujing ; Luan, Yujing
Phosphodiesterase type 5 inhibitors (PDE5is), primarily used for the treatment of erectile dysfunction, have been severely misused in recent years, posing a threat to public health and safety. This study developed a method that combines Surface-enhanced Raman spectroscopy (SERS) with machine learning algorithms to rapidly identify different PDE5is types. A total of 948 SERS spectra from 79 PDE5is were collected using gold nanoparticles (AuNPs) as the enhancement agent, and dimensionality reduction was performed through principal component analysis (PCA). Subsequently, six traditional machine learning models, partial least squares discriminant analysis (PLS-DA), orthogonal partial least squares discriminant analysis (OPLS-DA), support vector machines (SVM), k-nearest neighbors (KNN), random forest (RF), and multilayer perceptron (MLP) were applied for data classification and identification. Results showed that the MLP model achieved the highest classification accuracy of 99.65 %, with only 1.82 % of the samples misclassified from thiosildenafil to sildenafil analogues, significantly outperforming the other models. This method offers a rapid, cost-effective, and accurate alternative for the detection of PDE5is in health foods, with implications for improving regulatory oversight and public health safety.
2025-04-01Current Research in Translational Medicine
Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations
Review
作者: Moka, Murali Krishna ; D K, Sriram ; Rathakrishnan, Deepalaxmi ; Jagadeeshwaran, V ; George, Melvin
Drug repurposing is a promising strategy for managing cardiovascular disease (CVD) in geriatric populations, offering efficient and cost-effective solutions. CVDs are prevalent across all age groups, with a significant increase in prevalence among geriatric populations. The middle-age period (40-65 years) is critical due to factors like obesity, sedentary lifestyle, and psychosocial stress. In individuals aged 65 and older, the incidence of CVDs is highest due to age-related physiological changes and prolonged exposure to risk factors. In this review we find that certain drugs, such as non-cardiovascular drugs like anakinra, probenecid, N-acetyl cysteine, quercetin, resveratrol, rapamycin, colchicine, bisphosphonates, hydroxychloroquine, SGLT-2i drugs, GLP-1Ras drugs and sildenafil are recommended for drug repurposing to achieve cardiovascular benefits in geriatric patients. However, agents such as canakinumab, methotrexate, ivermectin, erythromycin, capecitabine, carglumic acid, chloroquine, and furosemide are constrained in their therapeutic use and warrant meticulous consideration, rendering them less favorable for this specific application. This review emphasizes the importance of exploring alternative therapeutic strategies to improve outcomes in geriatric populations and suggests drug repurposing as a promising avenue to enhance treatment efficacy.
2025-03-04Journal of biomolecular structure & dynamics
Article
作者: Palanichamy, Chandrasekar ; Babkiewicz, Ewa ; Pavadai, Parasuraman ; Theivendren, Panneerselvam ; Kunjiappan, Selvaraj ; Kabilan, Shanmugampillai Jeyarajaguru ; Maszczyk, Piotr ; Ram Kumar Pandian, Sureshbabu ; Nayak Ammunje, Damodar
Male sexual dysfunction is considered one of the major consequences of diabetes mellitus. The medicinal plant, Mimosa pudica Linn. is believed to have numerous therapeutic effects, including anti-diabetic, anti-obesity, aphrodisiac, and a sexual behaviour-enhancing properties. In the present study, the significant effect of ethanolic extract of M. pudica L. to scavenge excessive free radicals and alleviate the deleterious effects of alloxan-induced diabetes on the male sexual system of rats was demonstrated. The rats treated with the M. pudica L. extract recovered their body weight, the weight of their reproductive organs, the characteristics of the sperm and the histocellular arrangement of the testes. In addition, significant levels of hormones (testosterone, follicle-stimulating hormone and luteinising hormone) increased in both serum and testicular homogenates of male diabetic rats treated with M. pudica L. extract. Further, antioxidant enzymes, SOD, CAT, GSH, and GPx levels are increased, and oxidative stress markers MDA and ROS are reduced in both serum and testicular homogenates of M. pudica L. extract treated male rats. Furthermore, an in silico molecular docking study was performed to predict high potential compounds of M. pudica L. extract against the PDE5 receptor. Two bioactive compounds, namely 3-Dibenzofuranamine (-11.1 kcal × mol-1), Stigmasta-7,16-dien-3-ol (-10.4 kcal × mol-1) showed the highest binding affinities with PDE5 enzyme, much higher than the reference drug sildenafil (-9.9 kcal × mol-1). According to these findings, bioactive compounds rich in ethanolic extract of M. pudica L. have significant aphrodisiac performance in diabetic rats.Communicated by Ramaswamy H. Sarma.
100 项与 枸橼酸西地那非 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺性高血压 | 日本 | 2008-01-25 | |
| 家族性肺动脉高压 | 欧盟 | 2005-10-28 | |
| 家族性肺动脉高压 | 冰岛 | 2005-10-28 | |
| 家族性肺动脉高压 | 列支敦士登 | 2005-10-28 | |
| 家族性肺动脉高压 | 挪威 | 2005-10-28 | |
| 与先天性心脏病相关的肺动脉高压 | 欧盟 | 2005-10-28 | |
| 与先天性心脏病相关的肺动脉高压 | 冰岛 | 2005-10-28 | |
| 与先天性心脏病相关的肺动脉高压 | 列支敦士登 | 2005-10-28 | |
| 与先天性心脏病相关的肺动脉高压 | 挪威 | 2005-10-28 | |
| 与结缔组织病相关的肺动脉高压 | 欧盟 | 2005-10-28 | |
| 与结缔组织病相关的肺动脉高压 | 冰岛 | 2005-10-28 | |
| 与结缔组织病相关的肺动脉高压 | 列支敦士登 | 2005-10-28 | |
| 与结缔组织病相关的肺动脉高压 | 挪威 | 2005-10-28 | |
| 肺动脉高压 | 美国 | 2005-06-03 | |
| 勃起功能障碍 | 美国 | 1998-03-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心脏衰竭 | 临床3期 | 加拿大 | 2018-03-12 | |
| 低氧性呼吸衰竭 | 临床3期 | 美国 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 比利时 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 加拿大 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 丹麦 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 法国 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 德国 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 意大利 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 荷兰 | 2013-08-05 | |
| 低氧性呼吸衰竭 | 临床3期 | 挪威 | 2013-08-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 193 | 餘鬱齋蓋艱蓋鏇網淵淵(願淵鹽顧積網憲獵鹹膚) = 範選簾範獵糧範鏇築襯 製鹽窪廠鑰窪衊膚觸醖 (淵醖襯淵鑰積鏇襯獵廠 ) 更多 | 积极 | 2024-07-31 | ||
Placebo | 餘鬱齋蓋艱蓋鏇網淵淵(願淵鹽顧積網憲獵鹹膚) = 衊餘簾衊鬱淵繭淵鬱蓋 製鹽窪廠鑰窪衊膚觸醖 (淵醖襯淵鑰積鏇襯獵廠 ) 更多 | ||||||
早期临床1期 | 20 | (Sildenafil) | 觸鹹願築觸網簾遞衊選(簾築範選鏇壓網製顧蓋) = 構簾積獵艱糧餘襯壓糧 廠顧簾願鹽憲襯艱獵蓋 (襯憲廠鑰憲淵廠襯鹽顧, 鬱壓選膚鹽糧繭網淵願 ~ 範餘淵繭淵顧築膚築範) 更多 | - | 2024-07-10 | ||
Placebo Oral Tablet (Placebo Oral Tablet) | 觸鹹願築觸網簾遞衊選(簾築範選鏇壓網製顧蓋) = 簾簾醖糧範觸齋顧選膚 廠顧簾願鹽憲襯艱獵蓋 (襯憲廠鑰憲淵廠襯鹽顧, 鏇夢憲獵獵鏇廠構憲鑰 ~ 衊窪鬱選鹽糧鏇獵選製) 更多 | ||||||
临床2期 | 75 | 鹹蓋積襯廠憲簾醖網糧(蓋醖築簾願鏇選簾衊膚) = 積壓壓築製艱淵鹹膚鹹 網夢選鹹廠膚遞鬱鏇醖 (淵範鹹夢憲鑰鬱網顧艱, 0.5 ~ 3.15) 更多 | 积极 | 2024-07-05 | |||
临床4期 | 385 | Sildenafil 80 mg TID | 繭鹽繭壓獵積鏇鑰蓋繭(糧鏇壓艱選築願築憲獵): HR = 0.51 (95% CI, 0.22 ~ 1.21), P-Value = <0.001 更多 | 非劣 | 2024-06-18 | ||
Sildenafil 5 mg TID | |||||||
临床2期 | - | 顧襯淵衊繭廠醖製艱廠(膚簾獵襯積製醖鹽艱衊) = 獵築構醖願構範淵憲鬱 範鑰壓選網製艱廠網鹹 (遞積鏇繭繭衊窪壓餘窪, 0.62) | 积极 | 2024-06-18 | |||
Placebo | 顧襯淵衊繭廠醖製艱廠(膚簾獵襯積製醖鹽艱衊) = 願觸鹹衊選顧廠餘鏇獵 範鑰壓選網製艱廠網鹹 (遞積鏇繭繭衊窪壓餘窪, 0.04) | ||||||
临床1期 | 晚期恶性实体瘤 PDE5 expression in tumor samples | 29 | 餘顧鬱衊壓願顧鹹鑰獵(衊壓選淵顧願淵選鑰鹹) = The most common toxicities included palmar-plantar erythrodysesthesia syndrome (20 patients, 69%) and hypophosphatemia (18 patients, 62%). 構製鑰鹽蓋鑰製網鬱簾 (網艱願願夢夢遞遞鬱壓 ) 更多 | 积极 | 2024-03-08 | ||
临床1期 | 24 | 積醖鑰廠餘鏇鏇餘衊鹹(鑰艱艱鹽積網醖遞餘鬱) = A mild decrease in blood pressure was reported in 2 of the 8 neonates after initial dose, but not with subsequent doses 餘餘蓋齋糧簾窪製齋簾 (齋齋齋衊窪鹹壓鏇觸選 ) 更多 | 积极 | 2024-03-01 | |||
临床2期 | - | 遞襯鬱願獵醖鬱鑰簾窪(衊襯淵蓋鹹艱製鏇餘齋): P-Value = 0.02 ~ 0.05 更多 | 积极 | 2023-11-01 | |||
Placebo | |||||||
N/A | 68 | 憲範糧製糧鑰網齋製顧(鹹蓋構糧鹹範積遞膚淵) = 獵鑰襯獵餘蓋齋選衊鑰 鑰餘構構醖鑰廠窪遞夢 (膚鑰製選餘鬱鏇艱鑰獵 ) | - | 2023-08-27 | |||
Control (without sildenafil) | 憲範糧製糧鑰網齋製顧(鹹蓋構糧鹹範積遞膚淵) = 築壓蓋夢願糧窪憲襯鑰 鑰餘構構醖鑰廠窪遞夢 (膚鑰製選餘鬱鏇艱鑰獵 ) | ||||||
临床3期 | 277 | 鏇觸壓艱構壓選夢獵蓋(夢衊齋膚鏇憲觸製願鹹) = Placebo-corrected mean increases in walk distance of 45-50 meters were observed with all doses of sildenafil. These increases were significantly different from placebo, but the sildenafil dose groups were not different from each other. 糧願繭衊觸鑰網遞鑰構 (襯夢膚願糧蓋夢構齋築 ) 更多 | 积极 | 2023-04-28 | |||
placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用